CRSP - Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
2023-12-21 05:51:00 ET
"The thrill of victory and the agony of defeat."
That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (NASDAQ: CRSP) and Pfizer (NYSE: PFE) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.
But which of these two biopharmaceutical stocks is the better pick for a new bull market ? Motley Fool contributors Adria Cimino and Keith Speights make the arguments for CRISPR Therapeutics and Pfizer, respectively.
For further details see:
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock